Does Jardiance Cause Weight Loss?
Yes, Jardiance (empagliflozin) consistently causes weight loss across all studied populations, with reductions typically ranging from 2-4% of baseline body weight over 12-24 weeks of treatment. 1
Magnitude of Weight Loss
The FDA-approved drug label demonstrates clear, dose-dependent weight reduction across multiple clinical trials:
Monotherapy and combination therapy studies: Empagliflozin 10 mg produced 1.8-2.9% body weight reduction, while the 25 mg dose achieved 2.4-3.2% reduction compared to placebo (which showed 0.5-0.6% weight gain) 1
Head-to-head comparison: When compared directly to glimepiride over 52 weeks, empagliflozin 25 mg resulted in 3.9% weight loss versus a 2.0% weight gain with glimepiride—a clinically meaningful 5.9% difference between groups 1
Insulin combination therapy: Even in patients on high-dose insulin (mean 88-90 IU daily), empagliflozin produced 1.7-3.0% weight reduction versus placebo over 18-78 weeks 1
Clinical Context and Mechanisms
The weight loss occurs through glucosuria-induced caloric loss (approximately 200-300 calories daily excreted in urine) and mild osmotic diuresis. Current ADA guidelines classify SGLT2 inhibitors as having "intermediate" weight loss efficacy—less than GLP-1 receptor agonists but superior to DPP-4 inhibitors, sulfonylureas, and insulin 2.
Recent 2025 research confirms these effects extend beyond diabetes: a 12-week trial in patients with antipsychotic-induced weight gain showed empagliflozin 10 mg produced significant weight reduction comparable to metformin 1000 mg 3. Another 2025 study in prediabetic and diabetic patients demonstrated 3.8% weight loss (2.96 kg) over just 3 months, with greater reductions in men than women 4.
Important Clinical Considerations
The weight loss effect does not plateau quickly—studies show continued benefit through 52-104 weeks of treatment 1. The effect is maintained even when glucose-lowering efficacy diminishes at lower eGFR levels, as the mechanism is partially independent of glycemic control 2.
Common pitfall: Don't discontinue empagliflozin when eGFR falls below 45 mL/min/1.73 m². While glucose-lowering becomes minimal, continue the medication for cardiovascular and renal benefits (and weight management) until dialysis or transplantation 2.
The weight loss comes with additional cardiometabolic benefits including 3-4 mmHg systolic blood pressure reduction and improvements in triglycerides and HDL cholesterol 1, 5. However, counsel patients about increased risk of genital mycotic infections (2-10% incidence, dose-dependent) 6, 7.